• Rigel Pharmaceuticals reported third-quarter 2026 net product sales of $72.3 million, up 13% from a year earlier.
• VEPPANU generated $6.6 million in net product sales during its first six weeks of commercial availability.
• Year-to-date net product sales rose 17% to $194.2 million.
• Full-year 2026 sales guidance had a midpoint of $257.5 million, excluding VEPPANU.
• R289 could represent a market opportunity exceeding $1 billion in lower-risk myelodysplastic syndrome, according to the presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.